Please assess the completion status of the following clinical trial:

Trial Title: Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Duke employees who are enrolled in a Duke Health Plan and intend to remain employed at Duke for the next six months;~* Dependents of Duke employees who meet the above criteria;~* 18-65 years old;~* Currently smoke an average of at least 10 cigarettes per day;~* Willing to take Chantix or Zyban;~* Express a desire to quit smoking within the next 30 days.~Exclusion Criteria:~* Hypertension;~* Hypotension with symptoms (systolic \<90 mm Hg, diastolic \<60 mm Hg);~* Coronary heart disease;~* Lifetime history of heart attack;~* Cardiac rhythm disorder (irregular heart rhythm);~* Chest pains (unless history, exam, and ECG clearly indicate a non-cardiac source);~* Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);~* Extensive active skin disorder;~* Liver or kidney disorder (except kidney stones, gallstones);~* Gastrointestinal disease other than gastroesophageal reflux or heartburn;~* Active ulcers in the past 30 days;~* Currently symptomatic lung disorder/disease (including but not limited to COPD, emphysema, and asthma);~* Brain abnormality (including but not limited to stroke, brain tumor, and seizure disorder);~* Migraine headaches that occur more frequently than once per week;~* Recent, unexplained fainting spells;~* Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%);~* Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);~* Other major medical condition;~* Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide;~* Pregnant or nursing mothers;~* Current psychiatric disease (with the exception of anxiety disorders, OCD and ADHD);~* Current depression;~* Bulimia or anorexia;~* Alcohol abuse;~* Significant adverse reaction to bupropion/Wellbutrin/Zyban, Chantix/Varenicline or nicotine patches in the past.~* Use (within the past 30 days) of:~  * Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any other smoking cessation aid.~ * Medications that are known to affect smoking cessation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- varenicline (Chantix) (Type: ACTIVE_COMPARATOR): This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
- nicotine patches (Type: ACTIVE_COMPARATOR): This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
- bupropion (Zyban) and nicotine patches (Type: ACTIVE_COMPARATOR): This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues